Podcast Cruzamento André Correia e Daniel Guedelha

In today's CRUZAMENTO Podcast, André Correia e Daniel Guedelha talk with Hugo Barbosa who take us on a compelling journey from his beginnings in a small northern Portuguese town to a distinguished career spanning multiple countries. Hugo's insightful discussion delves into the clinical trials cycle, the evolution of drug development, and the transformative power of modern medical science. He talks about the challenges and innovations in pharmaceutical marketing, the critical role of global product teams (GPT), and the strategies for making lifesaving drugs accessible worldwide.



Raised in a small town in northern Portugal in the post-April Revolution fervor for democracy and challenging economic times, Hugo Barbosa 's roots are deeply founded in resilience and hope. With over 25 years in the pharmaceutical industry, including a decade in various international roles, Hugo has cultivated a rich professional journey. His career has taken him across seven cities in three different countries, where he has encountered remarkable individuals, immersed himself in diverse cultures, and broadened his understanding of the world. Hugo believes he can leave the world a little better than he found it. And he tries to do so through the people he interacts with every day, whether at work, at home or at leisure!



Contacts | Contactos:




CruzamentoPodcast.com



cruzamentopodcast@gmail.com



LinkedIN: Cruzamento



Twitter: @cruzamentofm



Facebook: @podcastcruzamento



Instagram: @cruzamentopodcast



YouTube: Podcast Cruzamento




Episode edited by João Cunha Studios

In today's episode of CRUZAMENTO Podcast, hosts André Correia and Daniel Guedelha sit down with biotech entrepreneur Nuno Prego Ramos to explore the intersection of technology and healthcare. Nuno shares insights into his groundbreaking work at Cellmabs, a biotech company focusing on cancer-specific antigens, and its landmark deal with BioNTech. He also introduces Valvian, his new venture targeting age-related diseases and hard-to-treat tumours using AI-driven immunotherapies. Nuno discusses the importance of developing proprietary AI models for healthcare, the challenges of data privacy, and the necessity of curating high-quality data. The conversation highlights Portugal's potential as a biotech hub, emphasising the need for talent retention, ecosystem development, and international collaboration to drive innovation in the life sciences sector.



Nuno Prego Ramos is the founder and CEO of Valvian, a Portuguese biotech company launched in January 2024 and announced at the East Coast Grand Investors Conference by Johnson & Johnson Innovation. With a law degree from the University of Lisbon further pursuing a Masters and Ph.D. in Biochemistry and immuno-oncology from Lisbon University, Nuno transitioned from a career in pharmaceuticals to focus on biotechnology. He founded CellmAbs in 2019, developing promising cancer therapies based on humanized monoclonal antibodies. Following the sale of these molecules to BioNTech in January 2024, he established Valvian, aiming to revolutionize cancer and longevity therapies through AI-driven research and to position Portugal as a global biotech leader.



Contacts | Contactos:




CruzamentoPodcast.com



cruzamentopodcast@gmail.com



LinkedIN: Cruzamento



Twitter: @cruzamentofm



Facebook: @podcastcruzamento



Instagram: @cruzamentopodcast



YouTube: Podcast Cruzamento




Episode edited by João Cunha Studios

Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Pedro Correa de Sampaio, a viver no Reino Unido, que transformou a sua paixão pela investigação em oncologia numa promissora startup biotecnológica, a Neobe Therapeutics. O Pedro partilha como foi a transição do mundo académico para a fundação da Neobe, uma empresa inovadora que utiliza engenharia genética para desenvolver terapias revolucionárias contra o cancro. Explica a analogia do "Cavalo de Tróia" para atacar tumores e discute os desafios de financiamento de startups no Reino Unido, além dos potenciais obstáculos e oportunidades em Portugal. Reflete sobre o talento e a ética de trabalho dos cientistas portugueses no exterior e a necessidade de mudança de mentalidade nas universidades e no sector empresarial português para fomentar o empreendedorismo científico. Uma conversa rica em insights sobre a interseção entre saúde, inovação e transformação digital.



Pedro Correa de Sampaio received his PhD in Oncology from the University of Cambridge, where he first developed his interest in understanding and targeting different components of the tumour microenvironment (TME). He initially focused on the study of angiogenesis -- the formation of new blood vessels in cancer, after which he moved to the MD Anderson Cancer Center in Houston, Texas. There, he developed methods to study the spatial interactions between TME components, and observed how they could prevent the effective infiltration of immune cells. That led him to move back to London and found Neobe, an early stage startup aimed at genetically engineering bacteria to disrupt these barriers and enable immunotherapy efficacy in solid tumours.



Other relevant references | Outras referências relevantes:




Neobe Therapeutics (website)




Contacts | Contactos:




CruzamentoPodcast.com



cruzamentopodcast@gmail.com



LinkedIN: Cruzamento



Twitter: @cruzamentofm



Facebook: @podcastcruzamento



Instagram: @cruzamentopodcast



YouTube: Podcast Cruzamento




Episódio editado por João Cunha Studios

In today's CRUZAMENTO Podcast, André Correia e Daniel Guedelha dive into the dynamic world of healthcare's digital transformation with Francisco Aguiar. From data privacy to precision medicine and wearable health tech, discover how organisations are reshaping patient care and driving innovation. Explore key trends and insights shaping the future of healthcare in this enlightening conversation.



Francisco Aguiar is a passionate project and people manager with over 10 years of experience in the life sciences industry. He leverages his data and analytics background to collaborate with key stakeholders and deliver impactful solutions that benefit both our customers and patients. Fostering career and leadership development within his team is a core value for Francisco. He believes in creating an environment where everyone can thrive and contribute their best work.



Other relevant references | Outras referências relevantes:




BI4ALL: Turning your data into actionable insights (website)



Emerald (website)




Contacts | Contactos:




CruzamentoPodcast.com



cruzamentopodcast@gmail.com



LinkedIN: Cruzamento



Twitter: @cruzamentofm



Facebook: @podcastcruzamento



Instagram: @cruzamentopodcast



YouTube: Podcast Cruzamento




Episode edited por João Cunha Studios

In this episode of Cruzamento Podcast, hosts André Correia and Daniel Guedelha dive into the intersection of technology and healthcare with special guest María Manso, CEO and co-founder of Tucuvi. Maria shares her journey from biomedical engineering to founding Tucuvi, a company dedicated to addressing healthcare capacity challenges using innovative technology. This platform enables autonomous phone consultations, leveraging empathetic conversational AI to engage patients and streamline healthcare delivery. Maria discusses Tucuvi's impact on patient care, collaboration with healthcare providers and pharmaceutical companies, and expansion into new markets. She highlights the importance of empathy in technology-driven healthcare solutions and invites listeners to connect with Tucuvi on LinkedIn for more information. This engaging conversation offers insights into the future of healthcare innovation and the role of startups in transforming patient-centred care.



María Manso is the Co-Founder and CEO of Tucuvi, a leading company in Conversational Artificial Intelligence in healthcare. Tucuvi works side by side with healthcare systems to help deliver quality care in the most efficient way possible to millions of patients. In 2024, she has been recognized as the Most Promising European Woman Innovator by the European Innovation Council.



Other relevant references | Outras referências relevantes:




Tucuvi (website)




Contacts | Contactos:




CruzamentoPodcast.com



cruzamentopodcast@gmail.com



LinkedIN: Cruzamento



Twitter: @cruzamentofm



Facebook: @podcastcruzamento



Instagram: @cruzamentopodcast



YouTube: Podcast Cruzamento




Episode edited by João Cunha Studios

In this episode of the CRUZAMENTO Podcast, hosts André Correia and Daniel Guedelha dive deep into the world of gene sequencing, rare diseases, and the future of healthcare with their guest, Tiago Magalhães. Tiago, a biologist turned bioinformatician, sheds light on the pivotal role of gene sequencing in modern healthcare and its potential to revolutionise patient care. From deciphering the intricacies of raw genomic data to the challenges and opportunities presented by initiatives like the Emirati Genome Program, Tiago provides valuable insights into the intersection of technology and healthcare. The conversation touches upon the high prevalence of rare diseases in the UAE, the impact of genomic data on drug discovery, and the evolving landscape of personalised medicine. Tiago also shares his thoughts on the future of genomics and the vital role of patient advocacy in shaping healthcare outcomes. Throughout the discussion, Tiago's expertise and passion for the subject shine, making complex topics accessible and engaging for listeners.



Who is Tiago Magalhães?



My name is Tiago Magalhães and I believe in the power of science and knowledge to make the world a better place. I have a Ph.D in genomics and an EMBA in management of research infrastructures. I am currently the Director of Bioinformatics at G42 Healthcare. G42Healthcare is a leading genomics organization, and currently has the largest cohort of long reads in the world. Before my current position, I was VP for Bioinformatics at Genomics Medicine Ireland and before that I was Executive Director at CCMAR, Portugal, a research organization for Marine sciences. I trained as a genomics scientist studying autism, diabetes, bowel cancer, and ancestry analysis. I have a very strong background in biology, namely in animal models, genetic screens, cell biology, microscopy and molecular biology. Words that describe my daily work: very large scale bioinformatics omics work (MGI, Illumina and ONT), analytics, computational biology, drug discovery, human resources supervision, business strategic thinking, and stakeholders management. Another facet of my CV is entrepreneurship, technology transfer and innovation, as I believe that science only makes sense when applied to solve societal challenges. I was the founder and CEO of a personalized medicine start-up, advised several genomics start-ups, and VCs on the genomics space. I am currently an expert for the H2020 European Union programs, and a reviewer for genomics journals. I have worked/studied in Portugal, Germany, US, Canada, East-Timor, Ireland, Brasil and the UAE.



Other relevant references | Outras referências relevantes:




Emirati Genome Program



Emirati Genome Program by G42.ai



UK Biobank




Contacts | Contactos:




CruzamentoPodcast.com



cruzamentopodcast@gmail.com



LinkedIN: Cruzamento



Twitter: @cruzamentofm



Facebook: @podcastcruzamento



Instagram: @cruzamentopodcast



YouTube: Podcast Cruzamento




Episode edited by João Cunha Studios